Skip to Content

Zealand Pharma A/S ZLDPF Stock Quote

| Rating as of


Last close prices updated as of May 26, 2023, 10:18 AM EST | USD
  • Last Close 38.25
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 38.25  –  38.25
  • Year Range 11.83  –  41.75
  • Market Cap 2.2320 Bil
  • Volume / Avg 184.0 /  438.6
  • Price / Sales 119.91
  • Price / Book 22.96
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ZLDPF

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ZLDPF

Company Profile ZLDPF

Business Description

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Sydmarken 11
Soborg, DK-2860, DNK
Industry Biotechnology
Employees 220

Competitors & Peers ZLDPF

Morningstar does not cover competitors or peers for this firm.

FAQs for Zealand Pharma A/S Stock

No. ZLDPF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ZLDPF’s market cap is 2.23 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ZLDPF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ZLDPF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ZLDPF’s historical performance against its industry peers and the overall market.